Saab Sammy, Rheem Justin, Sundaram Vinay
Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
Department Surgery, University of California at Los Angeles, Los Angeles, CA, USA.
Dig Dis Sci. 2015 Nov;60(11):3170-80. doi: 10.1007/s10620-015-3717-6. Epub 2015 May 26.
Hepatitis C virus (HCV) infection in the elderly population is a global medical burden and healthcare utilization concern. The majority of patients with hepatitis C in the USA are "baby boomers," who were born between 1945 and 1965. Consistently worldwide, HCV infection in elderly population is overrepresented and poses public health concerns. These individuals have been infected now for over two decades and are presenting with advanced liver disease. Traditionally, the use of pegylated interferon-based therapy has been limited in the elderly because of its adverse effects. The sustained virologic responses have also tended to be lower in the elderly than in younger adults. The emergence of non-interferon-based therapy with direct acting antiviral agents has expanded the pool of patients eligible for treatment. These agents have been found to be effective, tolerable, and safe in the elderly population.
丙型肝炎病毒(HCV)感染在老年人群中是一个全球性的医疗负担和医疗保健利用方面的问题。美国大多数丙型肝炎患者是“婴儿潮一代”,他们出生于1945年至1965年之间。在全球范围内,老年人群中的HCV感染比例过高,引发了公共卫生问题。这些人已经感染了二十多年,目前正出现晚期肝病。传统上,由于聚乙二醇化干扰素治疗的不良反应,其在老年人中的使用受到限制。老年患者的持续病毒学应答率也往往低于年轻成年人。基于直接抗病毒药物的非干扰素治疗的出现,扩大了 eligible for treatment的患者群体。已发现这些药物在老年人群中有效、可耐受且安全。 (注:eligible for treatment这里原文表述有误,应该是eligible for treatment的意思,可译为“适合治疗的” )